Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
February 2023—Qiagen announced an exclusive strategic partnership with Helix to advance companion diagnostics for hereditary diseases. Under the agreement, Qiagen will be the exclusive marketing and contracting partner in the United States for Helix’s companion diagnostic services.
February 2023—Vistapath has introduced its flagship product, the Sentinel pathology processing platform. The platform uses machine vision combined with artificial intelligence to assess specimens and create a gross report in a few seconds. It consists of the Sentinel module, which measures 17 in. W × 12 in. D × 15 in. H, and the touchscreen, which measures 15 in. W × 8 in. D × 11 in. H.
January 2023—PerkinElmer announced that the FDA has authorized the marketing of its Eonis SCID-SMA assay kit for in vitro diagnostic use by certified laboratories for the detection of spinal muscular atrophy and severe combined immunodeficiency in newborns. This is the first FDA-authorized assay for SMA screening in newborns in the United States, the company says, and is part of the company’s Eonis platform. The Eonis platform is a robust, flexible system that uses real-time PCR technology to screen for SMA and SCID using a single dried blood spot sample.
January 2023—QuidelOrtho will form a joint venture between Ortho Clinical Diagnostics Trading, a subsidiary of QuidelOrtho, and Shanghai Medconn Biotechnology, a subsidiary of Shanghai Runda Medical Technology, to develop and manufacture assays in China for QuidelOrtho’s Vitros platform. Following a successful assay pilot program, the companies expect to begin developing a broader set of assays early this year in parallel with building out the joint venture organization in the Shanghai and Beijing areas.
February 2023—Thermo Fisher Scientific has introduced more than 50 Absolute Q liquid biopsy assays for research use. The wet lab verified liquid biopsy assays provide highly sensitive, specific nucleic acid quantification, enabling single nucleotide polymorphisms detection down to 0.1 percent variant allele frequency.
January 2023—Roche has entered into a collaboration with Pfizer to help patients access resources and locate information about COVID-19 testing, available treatment options, high-risk factors that increase the chance of progressing to severe COVID-19, and ways to seek timely care. People can learn why early testing is important at symptom onset, which health conditions increase the risk of progressing to severe COVID-19, and what treatment options are available on covid19knowmore.com, a Pfizer website. The Pilot COVID-19 At-Home Test, distributed in the U.S. by Roche and manufactured by SD Biosensor, will include a QR code that directs people to the website.
January 2023—StatLab has introduced the Quantum S2 automated special staining platform. The 36-slide capacity platform provides automation for more than 25 special stains, including GMS and Warthin-Starry silver stains, and uses MasterTech special stains, which produce bright, crisp, high-clarity stains, the company says.
February 2023—Werfen has received five 2022 IMV ServiceTrak clinical laboratory awards in two categories. The company received best system performance and best service awards in the coagulation analyzers category, and awards for best customer satisfaction, best system performance, and best service in the blood gas category. This is the fourth consecutive year Werfen has been recognized in coagulation and the second time it has received all three awards in the blood gas category.
February 2023—BD has introduced a robotic track system for the BD Kiestra microbiology laboratory solution that automates lab specimen processing. The BD Kiestra third-generation total lab automation system allows laboratories to create a custom and flexible total lab automation configuration to connect multiple BD Kiestra modules.
February 2022—Qiagen has launched its EZ2 Connect MDx for use in diagnostic laboratories. The platform enables labs to purify DNA and RNA from up to 24 samples at the same time in as few as 30 minutes and uses magnetic-bead technology to extract nucleic acids from blood plasma, serum, stool, and other sample types. The benchtop instrument automatically pierces sealed cartridges, heats samples for incubation, and automates pipetting of beads, buffers, and enzymes. It can be used in research or IVD mode and monitored and managed remotely using the QIAsphere app.
